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A B S T R A C T
Background
Surgery has been used as part of breast cancer treatment for centuries; however any surgical procedure has the potential risk of infection.
Infection rates for surgical treatment of breast cancer are documented at between 3% and 15%, higher than average for a clean surgical
procedure. Pre- and perioperative antibiotics have been found to be useful in lowering infection rates in other surgical groups, yet there
is no consensus on the use of prophylactic antibiotics for breast cancer surgery.
Objectives
To determine the effects of prophylactic (pre- or perioperative) antibiotics on the incidence of surgical site infection (SSI) after breast
cancer surgery.
Search methods
For this second update we searched the Cochrane Wounds Group Specialised Register (searched 31 August 2011); the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 3); Ovid MEDLINE (2008 to August Week 3
2011); Ovid MEDLINE (In-Process & Other Non-Indexed Citations 30 August 2011); Ovid EMBASE (1980 to 2011 Week 34);
and EBSCO CINAHL (2008 to 25 August 2011). We applied no language or date restrictions.
Selection criteria
Randomised controlled trials of pre- and perioperative antibiotics for patients undergoing surgery for breast cancer were included.
Primary outcomes were rates of surgical site infection (SSI) and adverse reactions.
Data collection and analysis
Two review authors independently examined the title and abstracts of all studies identified by the search strategy, then assessed study
quality and extracted data from those that met the inclusion criteria.
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Main results
A total of nine studies (2260 participants) is included in the review. Eight studies evaluated preoperative antibiotic compared with no
antibiotic or placebo. One study evaluated perioperative antibiotic compared with no antibiotic. Pooling of the results demonstrated
that prophylactic antibiotics administered preoperatively significantly reduce the incidence of SSI for patients undergoing breast cancer
surgery without reconstruction (pooled risk ratio (RR) 0.71, 95% confidence interval (CI) 0.53 to 0.94). Analysis of the single study
comparing perioperative antibiotic with no antibiotic found no statistically significant effect of antibiotics on the incidence of SSI
(RR 0.11, 95% CI 0.01 to 1.95). No studies presented separate data for patients who underwent reconstructive surgery at the time of
removal of the breast tumour.
Authors’ conclusions
Prophylactic antibiotics administered preoperatively reduce the risk of SSI in patients undergoing surgery for breast cancer. Further
studies involving patients undergoing immediate breast reconstruction are needed as studies have identified this group as being at higher
risk of infection than those who do not undergo immediate breast reconstruction.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics to prevent surgical site infection after breast cancer surgery
Breast cancer accounts for one in 10 of all new cancer cases diagnosed and surgical removal of the breast is a common treatment approach.
An infection of the surgical wound is often a complication of surgery and taking antibiotics just before the operation significantly
reduces the chances of developing an infection. The review is not able to establish which antibiotic is most appropriate. No trials were
found which considered the effect of antibiotics when the operation involved immediate breast reconstruction.
B A C K G R O U N D
Breast cancer accounts for one in 10 of all new cancer cases di-
agnosed around the world each year (Bray 2004) and is the lead-
ing cause of cancer death in women (Pisani 1999). Surgery for
removal of breast cancer has been common practice for centuries
(Donegan 1995) and this is normally used as part of a multi-
faceted approach to care with the aim of curing the patient of their
cancer in early stage tumours or prolonging life for others (NICE
2002). Surgical intervention ranges from removing the breast and
associated axillary lymph nodes, to lumpectomy with or without
sentinel node biopsy (Harris 2004). Whilst the risk of breast can-
cer for men is only 1%, treatment for men is very similar to that of
women (Harris 2004). As with all surgical procedures, breast can-
cer surgery runs the risk of complications. One such risk is post-
operative surgical site infection (SSI), even though breast cancer
surgery is considered a ’clean surgical procedure’. Clean surgical
procedures, as defined by Haley 1985, are those which have a low
risk of bacterial contamination during the surgery.Some women
have immediate breast reconstruction; however this group of pa-
tients has a higher risk of SSI (Spauwen 2000).
Despite internationally recognised infection control guidelines
(Mangram 1999), the incidence of SSI in those being treated for
breast cancer is thought to range between 3% (Lefebvre 2000)
and 15% (Witt 2003). This is a higher incidence of infection
than the 3.4% SSI rate associated with clean surgical techniques
(Vazquez-Aragon 2003). A recent review (Pittet 2005) found that
women who had been treated for breast cancer and who had im-
mediate reconstruction had a SSI rate of between 0% and 53%,
whilst non-cancer patients undergoing the same reconstructive
surgery had an average rate of 2.5%. There are several factors that
are documented as increasing the risk of infection for surgical pa-
tients generally. These include: patient risk factors, e.g. diabetes,
obesity or smoking (Haley 1985; Mangram 1999); surgical tech-
nique, e.g. aseptic technique (Ritter 1988); and type of surgery,
e.g. whether the wound is contaminated (Gruendemann 2001).
In addition, surgery for breast cancer has several risk factors that
make this patient group more susceptible to infection, including
use of chemotherapy prior to surgery (neo-adjuvant chemother-
apy); technique of diagnostic biopsy; re-operation for recurrence
or to achieve better tumour margins; reconstructive surgery with
implants and seroma accumulation and drainage (Morris 1988;
Tran 2003). Infection may lead to significant morbidity for the
patient, delay in adjuvant treatment, such as radiotherapy, and
increased cost of care if the patient requires supplementary treat-
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ment due to infection (Coello 1993).
Pre- and perioperative antibiotics have been shown to reduce
the risk of postoperative infection in several patient groups (the
term “perioperative” refers to administration between induc-
tion of anaesthetic and the patient leaving the recovery room)
(Gruendemann 2001; Majoribanks 2004; SIGN 2008a). In col-
orectal surgery antibiotic prophylaxis has been found to reduce
long and short-term morbidity, decrease length of hospital stay
and lower the overall cost of care (SIGN 2008a). However, the use
of prophylactic antibiotics in preventing infection is still a contro-
versial issue and their routine use is not common in breast can-
cer surgery. Some feel that a clean surgical procedure should not
require prophylactic antibiotics (Sheridan 1994) and that the use
of pre- or perioperative antibiotics merely masks the symptoms of
infection until after the patient is discharged (Wagman 1990). In
addition increased antibiotic use may lead to antibiotic resistance
(PHLS 2000) and adverse effects such as clostridium difficile in-
fection that causes gastro-intestinal problems (SIGN 2008a). In
order to clarify the situation, this systematic review evaluated the
effectiveness of pre- or perioperative antibiotics in reducing the
incidence of postoperative infections in patients undergoing breast
cancer surgery.
O B J E C T I V E S
To determine the effects of prophylactic antibiotics on SSI after
breast cancer surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical trials
(where patients were allocated by quasi-random methods such as
alternation, case records numbers or days of the week).
Types of participants
People with breast cancer undergoing breast surgery with or with-
out immediate re-construction as part of their treatment.
We included studies that involvedmixedpatient groups (i.e. cancer
and non-cancer, other surgeries or breast implants not as part of
cancer treatment) as long as it was possible to extract separate data
for those undergoing surgery primarily to treat breast cancer.
Types of interventions
Any pre- or perioperative antibiotics used as prophylaxis where
there was no known infection and where the use of antibiotics
was the only systematic treatment difference between comparison
groups.
We only included trials of one antibiotic compared with another
if there was a control or placebo arm, as benefit from prophylactic
antibiotics has not yet been established in this patient group.
Definitions of key terms:
• ’Antibiotic regimen’ describes the characteristics of the
antibiotic treatment, i.e. type of antibiotic, route, dose, number
of doses and timing of administration.
• ’Preoperative antibiotic prophylaxis’ is antibiotic therapy
given within 24 hours prior to surgery, solely for prophylaxis (i.e.
not for an infection that is already suspected).
• ’Perioperative antibiotic prophylaxis’ is antibiotic therapy
administered between commencement of induction of surgery
and the patient leaving the recovery room.
Comparisons of interest were as follows.
• Preoperative antibiotic compared with no antibiotic or
placebo.
• Perioperative antibiotics compared with no antibiotic or
placebo.
• Head to head comparisons of antibiotics.
Types of outcome measures
Primary outcomes
1. Incidence of postsurgical breast surgical site (wound)
infection (SSI)*. Where possible, this should be reported as the
number of participants in each group with a clinically significant
infection. Research demonstrates that 98% of acute SSIs related
to non-implant breast surgery occur within 28 days (Mitchell
1999). However, where there is surgical re-construction,
guidelines recommend that this time is increased to one year post
surgery (Mangram 1999). Therefore we included all studies that
present data on acute SSI within one year of surgery.
2. Adverse reactions (e.g. anaphylaxis, gastro-intestinal or skin
rash).
*Surgical site infection: ideally this will be defined using outcomes
from a validated assessment tool such as ASEPSIS (Wilson 1986)
which are based on CDC definitions (Mangram 1999).
Secondary outcomes
1. Death.
2. Delay in adjuvant cancer treatment because of breast
wound infection.
3. Time to wound healing.
4. Time to infection.
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5. Readmission to hospital.
6. Cost of care (should be a comparison between the
treatment and control group).
Search methods for identification of studies
Electronic searches
See Appendix 1 for the search strategy used for the original version
of this review.
For the second update of this review we searched the following
electronic databases:
• the Cochrane Wounds Group Specialised Register (searched
31 August 2011);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2011, Issue 3);
• Ovid MEDLINE (2008 to August Week 3 2011);
• Ovid EMBASE (1980 to 2011 Week 34);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations August 30, 2011);
• EBSCO CINAHL (2008 to 25 August 2011).
We used the following search strategy in the Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Surgical Wound Infection explode all trees
#2 surg* NEAR/5 infection*
#3 surgical NEAR/5 wound*
#4 (postoperative or post-operative) NEAR/5 infection*
#5 MeSH descriptor Preoperative Care explode all trees
#6 (preoperative or pre-operative) NEXT care
#7 MeSH descriptor Perioperative Care explode all trees
#8 (perioperative or peri-operative) NEXT care
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Breast Neoplasms explode all trees with
qualifier: SU
#11 (breast NEXT cancer) NEAR/5 surg*
#12 (breast NEXT neoplasm*) NEAR/5 surg*
#13 (breast NEXT carcinoma*) NEAR/5 surg*
#14 MeSH descriptor Mastectomy explode all trees
#15 MeSH descriptor Mammaplasty explode all trees
#16 mastectomy or mammaplasty
#17 MeSH descriptor Breast explode all trees with qualifier: SU
#18 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17)
#19 MeSH descriptor Anti-Bacterial Agents explode all trees
#20 (antibiotic* or clindamycin or cefuroxime or cefuroxim or
ceftazidime or ofloxacin or levofloxacin or azithromycin or sul-
bactam or ampicillin or mezlocillin or oxacillin or vancomycin or
tobramycin or ciprofloxacin)
#21 (#19 OR #20)
#22 (#9 AND #18 AND #21)
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2, Appendix 3 and
Appendix 4 respectively.We combined theMEDLINE searchwith
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2011). We
combined the EMBASE and CINAHL searches with the trial fil-
ters developed by the Scottish Intercollegiate Guidelines Network
(SIGN) (SIGN 2008b). We applied no language or date restric-
tions.
Searching other resources
In addition, we screened references in all articles found by the
above search strategy for further studies. We contacted experts in
the field and interest groups to try andobtain access to unpublished
or ongoing work. We followed up conference proceedings and
grey literature that was considered to be potentially eligible for
inclusion by both authors by contacting the study authors for
further information.
Data collection and analysis
Selection of studies
Two review authors independently examined the title and abstract
of citations identified by the search.We obtained all reports of po-
tentially eligible trials as full-text articles and two review authors
independently applied the inclusion criteria, resolving disagree-
ments by discussion.
Data extraction and management
Two review authors independently extracted trial data using a
specifically designed data extraction tool. We extracted data on
study risk of bias (as defined below), antibiotic intervention (i.e.
drug name, dose route, duration of treatment), setting, source of
funding, length of follow-up and outcomes.
Assessment of risk of bias in included studies
For this update two review authors independently assessed each
included study using the Cochrane Collaboration tool for assess-
ing risk of bias (Higgins 2011). This tool addresses six specific
domains, namely sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome reporting
and other issues (e.g. extreme baseline imbalance) (see Appendix
5 for details of criteria on which the judgement was based). We
assessed blinding and completeness of outcome data for each out-
come separately. We completed a ’Risk of bias’ table for each el-
igible study. We discussed any disagreement amongst all review
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authors to achieve a consensus. We presented assessment of risk of
bias using a ’Risk of bias’ summary figure, which presents all of the
judgements in a cross-tabulation of study by entry. This display
of internal validity indicates the weight the reader may give the
results of each study.
Assessment of heterogeneity
We assessed heterogeneity between study results using the I2 statis-
tic (Higgins 2003). This examined the percentage of total varia-
tion across studies due to heterogeneity rather than chance. We
considered values of I2 over 75% to indicate a high level of hetero-
geneity and would have resulted in a random-effects model being
applied or not pooling results.
Data synthesis
Where possible for each trial we calculated the risk ratio (RR) of
infection and 95% confidence interval (95% CI), such that a risk
ratio of greater than one indicates a higher risk of infection in the
first group named. We reported continuous data (i.e. number of
days to infection), where possible, as mean difference (MD) with
95% CI.
Methods of synthesising the studies were dependent on trial qual-
ity, design and heterogeneity.We explored both clinical and statis-
tical heterogeneity. In the absence of clinical and statistical hetero-
geneity we applied a fixed-effect model to pool data. Where syn-
thesis was inappropriate we have presented a narrative overview.
Subgroup analysis and investigation of heterogeneity
As patients undergoing reoperation, reconstruction with or with-
out implants and patients receiving neo-adjuvant chemotherapy
are documented as having a higher risk of infection (Tran 2003)
we conducted a prespecified subgroup analysis of each of these
factors where there were sufficient data available. The proposed
subgroups were:
• patients undergoing immediate reconstruction without
implants (i.e. TRAM flap);
• patients undergoing immediate reconstruction with
implants (i.e. silicone or saline); and
• patients who have received chemotherapy (excluding
hormone treatment) prior to surgery.
Sensitivity analysis
Since there is evidence that the quality of allocation concealment
particularly affects the result of studies (Schulz1995), we examined
the effect of excluding studies judged to have inadequate allocation
concealment in a prespecified sensitivity analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
We identified two further studies which met the inclusion criteria
for this second update (Paajanen 2009; Yetim 2010) and excluded
two studies (Esposito 2006; Sanguinetti 2009). We identified a
further four abstracts which may be multiple publications of the
same study and have placed these in awaiting assessment whilst we
seek clarification from the study authors (Kumar 2005). In total
nine studies met the inclusion criteria for this version of the review
(Amland 1995; Bold 1998; Chow 2000; Gupta 2000; Hall 2006;
Paajanen 2009; Platt 1990; Wagman 1990; Yetim 2010).
Included studies
Participants
Of the nine studies, six (Bold 1998; Chow 2000; Gupta 2000;
Paajanen 2009; Wagman 1990; Yetim 2010) included women
only, one almost entirely women (Hall 2006) and two (Amland
1995; Platt 1990) may have contained male and female breast
surgery participants, although this could not be established from
the data presented in the report or by contacting the authors. All of
these studies included breast cancer patients as one of multiple pa-
tient groups being analysed. The studies were conducted between
1990 and 2009. Study sizes ranged between 44 (Yetim 2010) and
618 (Hall 2006). In total 2260 participants were included for
meta-analysis, 1134 in treatment arms and 1126 in control arms.
These studies were conducted in the hospital setting, were sin-
gle-centre trials and were conducted in seven different countries.
Country of origin for studies were: Australia (Hall 2006), Norway
(Amland 1995), United States of America (Bold 1998; Platt 1990;
Wagman 1990), Japan (Chow 2000), Finland (Paajanen 2009),
Turkey (Yetim 2010) and United Kingdom (Gupta 2000). All in-
cluded studies had been published.
Types of surgery
Types of participants included patients undergoing plastic surgery
(Amland 1995), herniorrhaphy or breast surgery (Platt 1990), ax-
illary lymph node dissection for breast cancer (Bold 1998) and pri-
mary, non-reconstructive surgery for breast cancer (Gupta 2000;
Hall 2006;Wagman 1990).One study (Chow 2000)was designed
to look at inflammatory rather than infective episodes, however
discrete data on infection rates were presented and therefore the
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studywas eligible for inclusion.One study looked at axillary lymph
node dissection as part of breast cancer treatment (Bold 1998).
One study (Paajanen 2009) looked at core needle biopsy and pri-
mary, non-reconstructive surgery for breast cancer. The three re-
maining studies (Gupta 2000;Wagman 1990; Yetim 2010) looked
solely at breast cancer patients receiving primary, non-reconstruc-
tive surgery for breast cancer.
Length of follow-up
Length of follow-up from surgery ranged from five days (Chow
2000) to six months (Yetim 2010). One study (Gupta 2000) fol-
lowed up patients between 10 and 14 days post discharge, but did
not document the length of hospital stay for these patients.
Source of funding
Three studies (Amland 1995; Bold 1998; Platt 1990) stated that
they were sponsored by a pharmaceutical company (Pfizer AS,
Smith Kline & Beecham and Smith Kline & French laboratories,
respectively).One study (Wagman 1990)was funded by the Amer-
ican Cancer Society and another (Paajanen 2009) by the Finnish
cultural foundation. The source of funding was not reported in
the other studies.
Antibiotics used
The antibiotics evaluated included:
• azithromycin, single dose decided according to body
weight, taken 8 pm the night before surgery (Amland 1995).
• oral clarithromycin (500mg) for 10 doses (Chow 2000).
• intravenous augmentin (1.2g) (Gupta 2000).
• a single dose of intravenous flucloxacillin (2g) (Hall 2006).
• cefazolin (six doses) (Wagman 1990).
• a single dose of intravenous dicloxacillin (1g) (Paajanen
2009).
• a single dose of cefonicid (1g) (Bold 1998; Platt 1990).
• collagen plus gentamycin sulphate (200mg) inserted under
the surgical wound prior to surgical closure (Yetim 2010).
Three studies (Bold 1998; Platt 1990; Wagman 1990) are very
similar in terms of length of follow-up, choice of antibiotic and
type of surgery undertaken. All studies had similar inclusion and
exclusion criteria.
Immediate reconstruction with or without implants
No eligible studies evaluating prophylactic antibiotics for re-
constructive surgery (with or without implants) were identified.
Whilst three studies (Amland 1995; Baker 2000; Franchelli 1994)
included patients undergoing reconstructive surgery, we excluded
the studies following scrutiny. It was not clear that the patients
had undergone surgery as part of breast cancer treatment (Amland
1995; Franchelli 1994) whilst one study was excluded because the
research was addressing the needs of dental patients who have ex-
isting implants (Baker 2000).
Neo-adjuvant chemotherapy
Two studies included patients who had received neo-adjuvant che-
motherapy (Bold 1998; Platt 1990).
Excluded studies
We excluded a total of 22 studies for the following reasons: two
were reviews, 10 were not RCTs or quasi RCTs, one was a multiple
drug comparison excluded as there was no placebo or control arm.
One compared different regimens and doses, but had no control
or placebo arm.We excluded one study as it could not be obtained
from the British Library. Five studies did not provide discrete data
for breast cancer patients and two were found to be studies focused
on other types of surgery (see Characteristics of excluded studies
table).
Risk of bias in included studies
See ’Risk of bias’ summary figure: Figure 1. Studies were judged
to be at overall unclear or high risk of bias if they were described
as unclear or at high risk of bias in the majority of the domains.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Sequence generation
Nine studies were described as RCTs, but only six adequately gen-
erated the randomisation sequence by reporting the use of com-
puter-generated numbers or sequences of blocks of 10 and were at
low risk of bias for this domain (Amland 1995; Bold 1998; Chow
2000; Gupta 2000; Hall 2006; Wagman 1990). Three studies
were classified as unclear as the authors failed to report themethod
by which randomisation sequence was generated (Paajanen 2009;
Platt 1990; Yetim 2010).
Allocation concealment
Adequate allocation concealment was described for six studies
(Bold 1998; Gupta 2000; Hall 2006; Paajanen 2009; Platt 1990;
Wagman 1990) and they were therefore at low risk of bias. Three
of these studies used the hospital pharmacy to generate the allo-
cation for participants (Bold 1998; Platt 1990; Wagman 1990).
One study stated that consecutive patients were allocated to group
by a computer program (Chow 2000) however the method of al-
location was not described and two studies used sealed opaque
sequentially numbered envelopes (Gupta 2000; Hall 2006). One
study reported the use of both hospital pharmacy as well as sealed,
opaque, sequentially numbered envelopes (Paajanen 2009). In the
remaining three studies the method of allocation concealment was
not described (Amland 1995; Chow 2000; Yetim 2010) and there-
fore they are classified as at unclear risk of bias.
Blinding
Blinding (participants and treatment providers - all
outcomes)
Adequate blinding of participants and treatment providers was
clearly reported in six trials and therefore these were at low risk
of bias (Amland 1995; Bold 1998; Gupta 2000; Paajanen 2009;
Platt 1990; Wagman 1990). Two trials were classified as having
inadequate blinding of both participants and treatment providers
mainly because the control groups were not blinded as they were
not given any treatment and were these two studies were at high
risk of bias for this domain (Chow 2000; Yetim 2010). Whilst
blinding was not specifically reported by Hall 2006 the antibiotic
was administered after the induction of anaesthesia therefore it is
possible that blinding was adequate but as there was no statement
by the study authors we judged this to be unclear.
Blinding (outcome assessors - all outcomes)
Seven studies described adequate blinding of outcome assessors
and these were at low risk of measurement bias. All antibiotic
compared with placebo studies stated that the key physician was
unaware of patient allocation until data collection was complete
(Amland 1995; Chow 2000; Gupta 2000; Hall 2006; Paajanen
2009; Platt 1990; Wagman 1990). In one study it remained un-
clear if the outcome assessors were adequately blinded (Bold 1998)
and in another (Yetim 2010) it was judged that the nature of the
collagen implants under the wound site would unblind the out-
come assessors.
Incomplete outcome data
In eight studies we judged the loss to follow-up to be low, with
similar numbers of participants lost in both control and treat-
ment groups and valid reasons given (Amland 1995; Bold 1998;
Chow 2000; Gupta 2000; Hall 2006; Paajanen 2009; Platt 1990;
Wagman 1990). In one study (Yetim 2010) the study was judged
to be unclear for this domain because the authors stated that pa-
tients would be followed up for six months post surgery but only
reported data at seven days.
We judged four studies to have undertaken an ITT analysis either
because they explicitly reported this or because there were no drop
outs from the study and the numbers of participants in the groups
analysed at the final follow up of the study were the same as those
randomised at the outset (Amland 1995; Gupta 2000; Hall 2006;
Paajanen 2009). Intention-to-treat analysis was not reported in the
other five studies (Bold 1998; Chow 2000; Platt 1990; Wagman
1990; Yetim 2010).
Selective reporting
The study protocols were not available but all the important out-
come measures stated in the methods section are reported in the
results and therefore we judged this domain to be at low risk of
bias for all studies.
Other potential sources of bias
We judged six trials to be at low risk of bias for this domain because
there was no imbalance in the baseline characteristics and the
studies appeared free from other forms of bias (Chow 2000; Gupta
2000; Hall 2006; Paajanen 2009; Wagman 1990; Yetim 2010). In
the remaining three studies (Amland 1995; Bold 1998; Platt 1990)
there was some funding reported from pharmaceutical companies
but it was unclear the extent of the industry involvement and we
have adopted a cautious approach by judging there to be a high
risk of bias.
8Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Effects of interventions
Preoperative antibiotics compared with placebo or
no antibiotic (eight trials, 2236 participants)
Six studies (Amland 1995; Bold 1998; Gupta 2000; Paajanen
2009; Platt 1990; Wagman 1990) compared preoperative antibi-
otics with placebo. Two studies (Chow 2000; Hall 2006) com-
pared preoperative antibiotics with no treatment.
Incidence of postoperative wound infection
All eight trials recorded incidence of wound infection as an out-
come. Results are presented as risk ratio (RR) where the risk ratio
is the risk of infection in the intervention group divided by the
risk of infection in the control group. A risk ratio of less than one
indicates fewer infections in the intervention group. Two studies
compared cefonicid with placebo (Bold 1998; Platt 1990), one
compared azithromycin with placebo (Amland 1995), one com-
pared augmentin with placebo (Gupta 2000), one compared cefa-
zolin with placebo (Wagman 1990), one compared flucloxacillin
with no treatment (Hall 2006), one compared dicloxacillin with
placebo (Paajanen 2009) and one compared clarithromycin with
no treatment (Chow 2000). One study (Chow 2000) reported no
infections in either group but in the remaining seven trials there
were fewer infections in the groups treated with antibiotics, al-
though this was not statistically significant in any of the individual
trials (Analysis 1.1).
In addition pooling the two studies which compared cefonicid
with placebo (Bold 1998; Platt 1990) showed a statistically signifi-
cant reduction in infection associatedwith preoperative antibiotics
(RR 0.56, 95% confidence interval (CI) 0.33 to 0.95) (Analysis
1.2).
We pooled all the trials using a fixed-effect model as there was no
evidence of heterogeneity (I2 = 0%). The pooled risk ratio shows
that giving preoperative antibiotics significantly reduces the risk
of wound infection after breast cancer surgery (RR 0.71, 95% CI
0.53 to 0.94) (Analysis 1.1). We carried out a sensitivity analysis
to exclude one study (Chow 2000), as this study had short follow-
up, only compared antibiotics with no antibiotic and reported in-
flammation rather than infection as its primary outcome. Sensi-
tivity analysis demonstrated no effect from removing Chow from
the pooled analysis.
One study (Bold 1998) documented infection rates in those who
received neo-adjuvant chemotherapy; there was no statistically sig-
nificant difference between the groups treated with cefonicid com-
pared with the placebo group (RR 0.21, 95% CI, 0.01 to 4.12)
(Analysis 1.3). Another study provided details of the number of
patients who had previously received chemotherapy (Platt 1990)
but did not report separate data on infection rates for these pa-
tients.
Since there is evidence that the quality of allocation concealment
influences study results (Schulz 1995) we examined the effect of
excluding studies judged to have inadequate allocation conceal-
ment in a prespecified sensitivity analysis. We judged two studies
(Amland 1995; Chow 2000) to have unclear allocation conceal-
ment. Removing these studies from the meta-analysis resulted in
a pooled RR of 0.71 (95% CI 0.53 to 0.95) which was still signif-
icantly in favour of prophylactic antibiotics.
Cost of care
One study (Bold 1998) reported the cost of care (Analysis 1.4).
This did not include the cost of operation or associated stay in
hospital, but calculated the cost of any additional care or med-
ications (i.e. antibiotic prophylaxis, postoperative antibiotics or
wound care). They found that the average cost per patient was
USD 49.80 in the antibiotic prophylaxis group and USD 364.87
in the control group. The majority of this cost difference was ac-
counted for in patients readmitted to hospital for wound compli-
cations.
Adverse reactions to treatment
Six studies (Bold 1998; Gupta 2000; Hall 2006; Paajanen 2009;
Platt 1990;Wagman 1990) reported adverse events (please refer to
other data tables for adverse effects from antibiotics under antibi-
otic versus none or placebo) (Analysis 1.5). Five studies reported
there were no adverse events (Bold 1998; Hall 2006; Paajanen
2009; Platt 1990; Wagman 1990) and one study (Gupta 2000)
reported 41 adverse events (23%) in the treatment group and 33
(18%) in the control group, but no details were reported on type
of adverse events. Although we contacted authors for clarification
about the nature of these events, they did not reply. The remain-
ing three studies made no mention of adverse events in the study
report.
Death
No studies presented information on deaths.
Time to wound healing
No studies presented information on time to wound healing.
Delay in adjuvant cancer treatment caused by SSI
No studies presented information on delays in adjuvant cancer
treatments due to SSI.
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Time to onset of infection
Three studies reported time to onset of infection (Analysis 1.6),
however they all provided the mean time to onset of infection and
not a range and therefore we have not combined this in a meta-
analysis. Two studies (Gupta 2000; Platt 1990) documented sim-
ilar mean times to onset of infection: 12 and 11 days in the in-
tervention group and 11 and 10 days in the control group respec-
tively.Wagman 1990 documentedmean time of onset of infection
of 17.7 days in the intervention group and 9.6 days in the control
group.
Readmission to hospital
Two studies (Bold 1998; Platt 1990) reported readmission rates
following treatment. Due to heterogeneity (I2 = 70.8%) we did
not pool results. One study (Bold 1998) reported statistically sig-
nificantly lower readmission rates in those treated with prophy-
lactic antibiotics (RR 0.11, 95% CI 0.01 to 0.88) (Analysis 1.7)
and a shorter duration of readmission (placebo group 5.9 days,
prophylaxis group 3.0 days); the other study found no reduction
in readmission rates (RR 1.0, 95%CI 0.29 to 3.42) (Analysis 1.7).
As such no conclusions can be drawn on this outcome.
Perioperative antibiotics compared with placebo or
no antibiotic (one trial, 44 participants)
One study (Yetim 2010) compared perioperative antibiotics with
no antibiotic.
Incidence of postoperative wound infection
This small study at overall high risk of bias presented wound in-
fection as an outcome. The study compared gentamycin-infused
collagen (Gentacoll) inserted perioperatively with no antibiotic.
There were no infections in the antibiotic-treated group compared
with four infections in the control group. Whilst the study au-
thor stated this to be significantly better in favour of the antibiotic
group this was not replicated in our analysis (RR 0.11, 95% CI
0.01 to 1.95) (Analysis 2.1).
Cost of care
The study did not report the cost of care.
Adverse reactions to treatment
The study did not report any adverse reactions to treatment.
Deaths
The study did not report any information on deaths.
Delay in adjuvant cancer treatment caused by SSI
The study did not report any information on delays in adjuvant
cancer treatment caused by SSI.
Time to onset of infection
The study did not report any information on the time to onset of
infection.
Readmission to hospital
The study reports that two patients in the control group had to be
readmitted for parenteral antibiotics as a result of wound infection.
No patients in the antibiotic group were readmitted.
D I S C U S S I O N
This review found that preoperative antibiotics significantly re-
duce the risk of SSI in people undergoing surgery for breast cancer
when compared with placebo or no treatment. Of the seven stud-
ies that reported data on adverse events only one found an increase
of events in the intervention group, however detailed information
about the nature of the adverse events was not given and adverse
events were generally poorly reported across the included stud-
ies. In addition data for some of the outcomes, including deaths,
delays in adjuvant cancer treatments, cost and readmissions were
reported by few of the included studies. We found one study that
evaluated perioperative antibiotics compared with no antibiotic;
this small study found that perioperative antibiotics did not sig-
nificantly reduce the incidence of SSI. We found no studies evalu-
ating antibiotics for breast reconstruction at the time of the initial
surgery.
We found no other systematic reviews or meta-analyses on the
effectiveness of antibiotic prophylaxis for breast cancer surgery.
Two previous non-systematic reviews (D’Amico 2001; Hall 2000)
did not draw any firm conclusions. Similar systematic reviews in
other types of clean surgery are scarce and have produced varied
results (Gillespie 2010; Sanchez-Manuel 2007).
We found only nine studies with a total of 2260 participants; not
many considering the number of people affected globally by breast
cancer.Whilst it is encouraging that a statistically significant result
was found it is possible that the numbers are not adequate to
evaluate fully the risks and benefits of antibiotic prophylaxis for
breast cancer surgery. In addition, although we found some trials
that included people having immediate breast reconstruction we
excluded themaswewere unable to obtain discrete data specifically
for breast cancer patients.
Whilst all efforts were made to obtain unpublished data, all the
included studies had been published, therefore there is potential
10Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for publication bias. Testing for publication bias was not done due
to the small number of studies obtained.
Although there was no statistical heterogeneity only two studies
compared the same antibiotic using the same regimen (Bold 1998;
Platt 1990), therefore we were unable to make conclusions about
the most effective antibiotic and regimen. Other recent research
has, however, recommended that antibiotic prophylaxis should
generally be administered as a single dose preoperatively in order
to maximise benefit and minimise adverse effects from treatment
(SIGN 2008a).
In general the included trials were at low risk of bias for the
main domains of sequence generation and allocation concealment.
Three studies had unclear allocation concealment (Amland 1995;
Chow 2000; Yetim 2010) and excluding these studies from the
analysis made little difference to the result. One study (Chow
2000) had a follow-up of only five days. As the average time to on-
set of infection in the other included studies ranged between 11 to
17.7 days it may have been appropriate to specify in the protocol
a minimum length for follow-up. However, excluding data from
this study made no difference to the overall outcomes. However,
we judged one study (Yetim 2010) which compared perioperative
antibiotics with no antibiotic to be at high risk of bias overall due
to a failure of blinding and insufficient information given regard-
ing selection bias.
Overall, there are sufficient data from this review to suggest that
antibiotic prophylaxis reduces surgical site infections in those un-
dergoing non-reconstructive breast cancer surgery. However fur-
ther research would be required to establish the best protocols for
practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Preoperative prophylactic antibiotics reduce the risk of a SSI in
people undergoing breast cancer surgery. However, this review
does not establish the most effective antibiotic regimen to use.
Implications for research
Further large, high-quality randomised controlled trials are needed
to establish the most effective prophylactic antibiotic protocols.
Analysis of secondary outcomes, such as adverse events, delays
in adjuvant cancer treatments and costs of care, would aid the
development of well considered and useful protocols and standards
for practice. In addition trials need to evaluate the use of antibiotics
in women undergoing immediate breast reconstruction.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amland 1995
Methods RCT: randomisation via computer-generated blocks of 10
Loss to follow-up: < 20%
Intention-to-treat: unclear
Power calculation unclear as not stated by the author
Reliable primary outcome: done
Participants Male and female. Age 6 years or above. Admitted for plastic surgery and able to give
informed consent.
Trial exclusion criteria: intolerance to trial drug, terminal illness or immunosuppression,
serious underlying disease, pregnant or breast feeding, received antibiotics in the 2 weeks
prior to surgery, malabsorption illnesses, receiving carbamazepine or cyclosporins, renal
or hepatic impairment, history of mental illness
Total breast excision participants: 76
Study included breast reconstruction and implants, which have not been included in this
analysis as the author could not be contacted to find out if reconstruction was secondary
to cancer treatment
Interventions I) Azithromycin - single dose. Dose according to body weight. Dose taken 8 pm the
night before surgery (n = 42)
C) Placebo used but no details provided (n = 34)
Outcomes Infection rates
Adverse effects
Notes Length of follow-up: 30 days
Funding organisation not stated
Country of origin: Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was performed in
blocks of 10 patients using a randomised
chart”
Comment: computer-generated blocks of
10. Method of generating the random
schedule reported
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: reported as placebo-controlled,
double-blind study (no further detail
given)
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Amland 1995 (Continued)
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Comment: reported as placebo-controlled,
double-blind study (no further detail
given)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “Blinding was maintained until ev-
ery patient had completed follow-up and
all diagnosis of wound infection had been
made”.
Comment: the wound was assessed “by
the physician” using a “specifically designed
wound assessment chart”. It was judged
that the physician undertaking the wound
assessment was likely blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “the inclusion of these patients in
the final analysis after the intention to treat
principle did not alter the end result signif-
icantly.”
Comment: only 1 patient was lost to fol-
low-up (placebo group)
Selective outcome data Low risk Comment: the study protocol was not
available, however, the results section
clearly reports the incidence of wound in-
fection using a prespecified scoring system.
The study states “there were 8 wound in-
fections in the azithromycin group and 32
in the placebo group.”
Other sources of potential bias High risk Comment: in the acknowledgements the
authors state “the present work was sup-
ported by Pfizer AS.” This is a pharmaceu-
tical company. However, the study appears
to be free of any other source of bias
Bold 1998
Methods RCT: randomisation using computer-generated blocks
Loss to follow-up: < 20%
Intention-to-treat: unclear
Power calculation: unclear, stated as under-powered
Clear definition of infection
Participants All female; 18 years old or above undergoing axillary lymph node dissection
Excluded if: there was history of allergy to cephalosporin, aspirin use within 5 days,
recent antibiotic use or infection, pregnancy or breast feeding, wound infection from
surgery in the past 4 weeks, hepatic or renal impairment, diabetes, inflammatory breast
cancer, concomitant isolated limb perfusion or those undergoing immediate breast re-
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construction
Total number of patients randomised = 200
22 excluded after randomisation
Of these, 141 were confirmed breast cancer patients
Interventions I) Cefonicid 1 g, intravenously 60 minutes prior to operation (n = 88)
C) Placebo used was normal saline as per antibiotic regime (n = 90)
Outcomes Infection rates
Re-hospitalisation rates
Cost of care
Adverse events
Notes Length of follow-up: 4 weeks post surgery
Funded by SmithKline Beecham
Country of origin: USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was accomplished
with a computer-generated block randomi-
sation table”.
Comment: computer-generated blocks
used. Method of generating the random
schedule reported
Allocation concealment (selection bias) Low risk Comment: hospital pharmacy performed
randomisation and provided placebo or an-
tibiotic in identical IV bags
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: ”Blinding of antibiotic administra-
tion was accomplished through the hospi-
tal pharmacy.” The authors go on to state
“[pharmacy] provided the placebo or ce-
fonicid in identical intravenous bags”
Comment: participants likely blinded
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Quote: “Blinding of antibiotic administra-
tion was accomplished through the hospi-
tal pharmacy.” The authors go on to state
“[pharmacy] provided the placebo or ce-
fonicid in identical intravenous bags”
Comment: treatment provider likely
blinded
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Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Quote: “patients were followed up in an
outpatient clinic andmonitored for signs of
symptoms of infection.” The authors go on
to say “a research nurse also contacted the
patient and referring physician for wound
follow up for 4 weeks after surgery”
Comment: no comment is made as to
whether the assessors remained blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Twenty-two patients were ex-
cluded from the analysis because of pro-
tocol violations”.10 were from the placebo
group and 12 from the treatment group.
This left 90 patients in the placebo group
and 88 patients in the cefonicid group.
Comment: the reasons for exclusion seem
valid and are unlikely to introduce bias,
overall the loss to follow-up was less than
20%
Selective outcome data Low risk Quote: in the introduction to the study
the authors state “the study was under-
taken to determine whether a single dose of
cephalosporin could decrease the incidence
of post operative wound infection”. They
go on to state “the results would be subject
to a cost benefit analysis”
Comment: the results clearly document the
incidence of wound infection in table II as
well as a cost benefit analysis in table III
Other sources of potential bias High risk Comment: the paper states “the study was
sponsored in part by a grant from Smith
Kline & Beecham laboratories”. This is
a pharmaceutical company. However, the
study appears to be free of any other source
of bias
Chow 2000
Methods RCT: computer-generated sequence
Loss to follow-up: < 20%
Intention-to-treat: not done
Power calculation: unclear
Clear definition of infection: unclear. Addressed inflammation rather than infection
Participants All females diagnosed with breast cancer and undergoing mastectomy
Total patients randomised: 56 with 2 being excluded after randomisation
Excluded if: pregnant, diabetic, hepatic or renal impairment,myasthenia gravis, tendency
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to bleeding, immunosuppression or antibiotics within the preceding 2 weeks
Interventions I) Clarithromycin 500 mg orally first dose commenced the day prior to surgery (n = 28)
. Treatment continued twice daily for 3 days post surgery.
C) Control group received no placebo (n = 24)
Outcomes Inflammatory responses
Infection rates
Flap necrosis (stated as minor in both groups)
Pain
Range of movement
Notes Length of follow-up 5 days post surgery
Country of origin: Japan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “consecutive patients (except those
excluded) were enrolled and randomised
into two groups by computer”.
Comment: randomised into 2 groups by
computer. Method of generating the ran-
dom schedule reported
Allocation concealment (selection bias) Unclear risk Comment: no further information is given
on the randomisation process
Blinding (performance bias and detection
bias)
Participants
High risk Quote: “Patients in the study group were
given oral clarithromycin. Patients in the
control group did not receive any clar-
ithromycin.”
Comment: control group received no treat-
ment
Blinding (performance bias and detection
bias)
Treatment Provider
High risk Quote: ”Patients in the study group were
given oral clarithromycin. Patients in the
control group did not receive any clar-
ithromycin.”
Comment: control group received no treat-
ment
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “All surgeons and medical staff re-
sponsible for assessing the outcome were
unaware of the randomisation results be-
cause separate prescription sheets were
given for the clarithromycin prescription”.
Comment: blinding of outcome assessor
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achieved
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “fifty six patients with breast can-
cer were recruited for the randomised trial.
Two patients in the control group dropped
out due to refusal of venepuncture.”
Comment: the number lost to follow-up is
low and the reason was valid
Selective outcome data Low risk Comment: the study protocol was not
available, however, the outcomes of this
study included postoperative wound infec-
tion as well as evidence of the systemic in-
flammatory response syndrome. This was
documented in the introduction to the
study and in the outcomes. The results dis-
cuss the changes in several inflammatory
markers and the results of blood culture
tests. The authors state “no patient devel-
oped a wound infection”
Other sources of potential bias Low risk Quote: “There were no significant differ-
ences between the two groups in terms of
age, area of dissection, blood loss, operation
time, and the amount of parenteral fluid
administered during the perioperative pe-
riod”.
Comment: there was no imbalance in the
baseline characteristics and the study seems
to be free from other forms of bias
Gupta 2000
Methods RCT: randomisation sequence generated by computer
Loss to follow-up: < 20%
Intention-to-treat: not done, 6 patients excluded from the analysis
Power calculation: done, but under-powered
Clear definition of infection: done; predefined clinical indicators
Participants All female; 18 years of age or above
Total number: 357
44 excluded after randomisation
Exclusion criteria: known penicillin allergy, infection within 72 hours pre-surgery, preg-
nant, on other antibiotics or with hepatic or renal impairment
Treatment group: 177
Placebo group: 180
Diagnosis of breast cancer. Receiving mastectomy or wide local excision with or without
axillary
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Interventions I) Augmentin 1.2 g intravenous. Single dose. Given perioperatively (after induction but
before first incision).
C) Placebo: normal saline as per treatment regime
Outcomes Infection rate
Adverse events
Time to wound healing
Notes Follow-up for 10 to 14 days post discharge
Funding not stated
Country of origin: UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized to re-
ceive the antibiotic or placebo (20 ml 0.9%
sterile saline) by reference to a computer
generated list”.
Comment: computer-generated list used.
Method of generating the random schedule
reported
Allocation concealment (selection bias) Low risk Quote: ”The randomization list was gen-
erated by computer. The randomization
codes were kept in sealed envelopes. Codes
were sequentially allocated to randomized
patients. Neither the patient nor any of the
staff involved with this study were aware of
the allocation of treatment until after the
study had been completed.”
Comment: sealed, opaque, sequentially-
numbered envelopes
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “Patients were randomized to re-
ceive the antibiotic or placebo (20 ml 0.9%
sterile saline).” The administration of an-
tibiotic is then described “Where the study
agent was administered the anaesthetist
was instructed to reconstitute the antibiotic
from vials of sterile powder. It was then ad-
ministered to the patients as a single intra-
venous bolus injection through a peripher-
ally placed 22 gauge intravenous cannula,
shortly after the induction of anaesthesia”.
Finally the author state “neither the patient
nor any of the staff involved with this study
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were aware of the allocation of treatment
until after the study had been completed”.
Comment: the study is described as ”a
prospective, randomised, observer blind,
placebo-controlled study“. Participants
were blinded
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Quote: ”Patients were randomized to re-
ceive the antibiotic or placebo (20 ml 0.9%
sterile saline).” The administration of an-
tibiotic is then described “Where the study
agent was administered the anaesthetist
was instructed to reconstitute the antibiotic
from vials of sterile powder. It was then ad-
ministered to the patients as a single intra-
venous bolus injection through a peripher-
ally placed 22 gauge intravenous cannula,
shortly after the induction of anaesthesia”.
Finally the authors state “neither the patient
nor any of the staff involved with this study
were aware of the allocation of treatment
until after the study had been completed”.
Comment: healthcare providers blinded.
The anaesthetist was not blinded but took
no further part in the study
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “At no time until the breaking of
the code was the investigator made aware
of whether the active agent or the placebo
was administered, somaking this study ‘ob-
server blind”.
Comment: outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Protocol violations resulted in six
patients being excluded from the intention-
to-treat group”. Table 1 shows that 357 pa-
tients were randomised and screened and
351 patients were “valid for efficacy anal-
ysis”. The table also states that 313 pa-
tients “completed study”. No information
is given on these 44 patients who did not
complete the study.
Comment: 3 patients were lost from each
group for the efficacy analysis, but the study
reports that an intention-to-treat analysis
was undertaken on 351 patients
Selective outcome data Low risk Quote: the methods section details the pri-
mary and secondary outcomes. “The pri-
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mary endpointwas the incidence ofwound
infection. Secondary endpoints included
febrile morbidity, duration of post-oper-
ative hospital stay, delay in progressing
to chemotherapy radiotherapy or surgical
cosmesis due to wound infection and the
incidence of chest or urinary infection, sep-
ticaemia or other infections”
Comment: in the results the incidence of
wound infections are clearly shown in table
6. The number of secondary endpoints is
also documented
Other sources of potential bias Low risk Comment: the study appears to be free of
other sources of bias
Hall 2006
Methods RCT: computer-generated random numbers arranged into blocks of 10
Intention-to-treat analysis: done
Power calculation: done
Reliable primary outcome: done
No loss to follow-up
Participants 618 (616 women and 2men). Scheduled for non-reconstructive breast surgery. Excluded
if penicillin hypersensitivity, reconstructive surgery, warfarin therapy, antibiotics within
72 hours, phenytoin therapy or existing infection. Only 2 patients (one in each group)
had received preoperative chemotherapy
Interventions I) Single IV dose of 2 g flucloxacillin administered over at least 5 minutes immediately
after the induction of general anaesthesia
C) No treatment
Outcomes Infection rates
Adverse effects
Cellulitis
Wound scores
Notes Follow-up: 42 days
Country of origin: Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to a group
using computer-generated random num-
bers arranged into blocks with a cell size of
10”.
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Comment: computer-generated list used.
Method of generating the random schedule
reported
Allocation concealment (selection bias) Low risk Quote: “Concealment was achieved by
placing the group allocation into opaque,
serially numbered envelopes that were
monitored to detect breaches of the ran-
domisation protocol”.
Comment: allocation concealment
achieved
Blinding (performance bias and detection
bias)
Participants
Unclear risk Comment: the study hadnoplacebo for the
control group, however, the authors state
“Patients in the study group received flu-
cloxacillin 2 g administered intravenously,
over at least 5 min, immediately after the
induction of general anaesthesia”
As the antibiotic was given after the induc-
tion of anaesthesia by an anaesthetist it may
be assumed that participants were blinded
but this was not reported in the study
Blinding (performance bias and detection
bias)
Treatment Provider
Unclear risk Comment: the study hadnoplacebo for the
control group, however, the authors state
“Patients in the study group received flu-
cloxacillin 2 g administered intravenously,
over at least 5 min, immediately after the
induction of general anaesthesia”
As the antibiotic was given after the induc-
tion of anaesthesia by an anaesthetist it may
be assumed that treatment personnel was
blinded but this was not reported in the
study
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “All assessments [of wound infec-
tion] were performed without any knowl-
edge of the patient’s allocated group”
Comment: outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Figure 1 shows 618 patients
randomised to either control or flu-
cloxacillin. All patients were followed up at
42 days. There was no loss to follow-up
Selective outcome data Low risk Quote: ”Wound infection was the primary
endpoint. It was defined as either the dis-
charge of pus, or a serous discharge contain-
ing pathogenic organisms. Wounds were
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also evaluated using a previously validated
scoring system”. In the results the authors
clearly document the incidence of wound
infection “Both groups had a similar rate of
postoperative wound infection: ten of 311
(3.2 per cent) in the flucloxacillin group
and 14 of 307 (4.6 per cent) in the control
group.”
Comment: the study protocol was not
available but the important outcome mea-
sures stated in the methods section are re-
ported in the results
Other sources of potential bias Low risk Comment: the study appears to be free of
other sources of bias
Paajanen 2009
Methods RCT: method of randomisation not reported
No loss to follow-up
Intention-to-treat analysis: done as all the participants were analysed in the groups to
which they were randomised
Power calculation: unclear as not stated by the author
Reliable primary outcome: done
Clear definition of infection: done
Participants All females patients undergoing non-reconstructive breast cancer surgery between years
2004 and 2007 were included
Total number: 292
Exclusion criteria patients with lack of consent, penicillin hypersensitivity, logistic failure
Treatment group: 144
Control group: 148
Diagnosis of breast cancer. Confirmed preoperatively by mammographic stereotactic or
ultrasound-guided core needle biopsy
Interventions I) Intravenous 1 g of dicloxacillin in a 100 ml bottle. Single dose 30 minutes before
surgery.
C) Placebo infusion of 100 ml of saline
Outcomes Infection rates
Notes Follow-up: 30 days
Country of origin: Finland
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomised to
receive either an intravenous single dose of
1 g of dicloxacillin in a 100 ml or a placebo
infusion of 100 ml of saline 30 min prior
to surgery.”
Comment: method of generating the ran-
dom schedule not reported
Allocation concealment (selection bias) Low risk Quote: “The hospital pharmacy generated
allocation using sealed opaque sequentially
numbered envelopes.”
Comment: allocation concealed using
sealed opaque sequentially numbered en-
velopes
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “The research group including the
operating surgeon, research nurses, other
medical staff, and study participants, were
blinded to the participant’s allocation.”
Comment: participants were blinded ade-
quately
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Quote: “The research group including the
operating surgeon, research nurses, other
medical staff, and study participants, were
blinded to the participant’s allocation.”
Comment: healthcare providers were
blinded adequately
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “All assessments were performed
without knowledge of the patient’s assigned
group.”
Comment: outcome assessors were blinded
adequately
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there was no loss to follow-up.
Table 3 depicts that all the randomised
participants were analysed in the group to
which they were allocated
Selective outcome data Low risk Quote: the authors state that SSI was the
primary endpoint. A clear definition of in-
fection is documented. The results state
“The rate of postoperative SSI was 5.6%
(8/144) in the dicloxacillin group and 8.
8% (13/148) in the placebo group.”
Comment: the study protocol was not
available but the important outcome mea-
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sures stated in the methods section are re-
ported in the results
Other sources of potential bias Low risk Quote: “The patient characteristics and
risk factors for SSI were similar in the an-
tibiotic prophylaxis and placebo groups.”
Comment: there was no imbalance in the
baseline characteristics and the study seems
to be free from other forms of bias
Platt 1990
Methods RCT; randomisation via blocks of 10
Loss to follow-up: < 20%
Intention-to-treat: unclear
Power calculation: adequate for the study as a whole, but may be under-powered for the
breast group
Clear definition of infection: done
Participants Included male and female patients aged 18 or above having mastectomy, lumpectomy,
excisional breast biopsy, axillary node clearance or reduction mammoplasty. Included
are those who speak English, lived within 35 miles of the hospital, have no recognised
infection at the time of surgery, recent antibiotic use or known allergy to beta-lactam
antibiotics.
Total number of participants: 606
18 years old or over
Interventions I) Cefonicid 1 g intravenous. Within 90 minutes pre-surgery (n = 303). Dose regime:
single dose.
C) Placebo was a mixture of glycerin, mannitol and riboflavin given as per the treatment
regime
Outcomes Infection rate
Adverse reaction to treatment
Time to onset of infection
Associated morbidity from wound infection
Economic evaluation
Other infective episodes
Notes Length of follow-up: 4 to 6 weeks
Sponsored by Smith, Kline and French Laboratories
Country of origin: USA
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: ”patients were randomly assigned
separately in blocks of 10 to receive cefoni-
cid or placebo.”
Comment: method of generating the ran-
dom schedule not reported
Allocation concealment (selection bias) Low risk Quote: “treatment codes were not known
by anyone at the participating centres un-
less the sealed opaque label attached to each
vial was opened.” They go on to state “in-
vestigators were required to return these la-
bels intact.”
Comment: allocation concealment
achieved
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: study described as a “Ran-
domised, double-blind trial”. “Cefonicid
and placebo were supplied in identical
numbered vials. The authors state “treat-
ment codes were not known by anyone at
the participating centres unless the sealed
opaque label attached to each vial was
opened.” They go on to state “investigators
were required to return these labels intact”.
Comment: participants were blinded ade-
quately
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Quote: study described as a “Ran-
domised, double-blind trial”. “Cefonicid
and placebo were supplied in identical
numbered vials. The authors state “treat-
ment codes were not known by anyone at
the participating centres unless the sealed
opaque label attached to each vial was
opened.” They go on to state “investigators
were required to return these labels intact.
”.
Comment: treatment providers were
blinded adequately
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “drug assignments were not known
during any followup evaluations, including
non scheduled visits for suspected wound
infection.” They repeat this in the surveil-
lance of wound infection paragraph “all in-
vestigators were unaware of the treatment
codes until the last evaluation was com-
pleted.”
Comment: automated data processing and
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analyses in laboratory. Outcome assessor
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: table 1 documents numbers of
and reasons for exclusion of patients from
analysis after randomisation. 50 patients
from the treatment group and 51 from the
control group were excluded. Similar rea-
sons for exclusion were documented for
both groups. No separate exclusion data are
given for the breast cancer patients
Overall the loss to follow-up was less than
20% and therefore judged to be adequate
Selective outcome data Low risk Comment: the study protocol was not
available, however, the incidence of wound
infection was the primary outcome mea-
sure. The authors document the definition
of a wound infection clearly. The results are
displayed in table 4. They are separated for
breast surgery verses hernia surgery
Other sources of potential bias High risk Comment: the paper states “the study was
supported by a grant from Smith, Kline &
French laboratories”. This is a pharmaceu-
tical company. However, the study appears
to be free of any other source of bias
Wagman 1990
Methods RCT: random numbers table generated by dept of biostatistics
Loss to follow-up: < 20%
Intention-to-treat: unclear
Power calculation: unclear
Clear definition of infection: done; predefined clinical indicators
Participants All breast cancer surgery except re-construction
Excluded were those with a history of allergy to the study antibiotic or receiving other
antibiotics
Total number of participants: 118
Interventions I) Cefazolin 25 mg per kg. Intravenous. First dose within 30 minutes pre-surgery. Dose
regime: 6 doses at 6-hour intervals (n = 59).
C) Placebo: normal saline bolus as per the treatment regime (n = 59)
Outcomes Infection rates
Adverse events
Time to onset of infection
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Affect of length of surgery
Affect of pre-surgery biopsy
Notes Length of follow-up: 30 days postoperative
Country of origin: USA
Sponsored by the American society career development award
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed in
the Pharmacy using a table of random
numbers generated by the Department of
Biostatistics”.
Comment: random number tables used.
Method of generating the random schedule
reported
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed in
the Pharmacy using a table of random
numbers generated by the Department of
Biostatistics”.
Comment: central allocation, i.e. phar-
macy-controlled
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “The patient, surgeon and Infec-
tion Control office had no knowledge of
the patient assignments”.
Comment: blinding of participants done
Blinding (performance bias and detection
bias)
Treatment Provider
Low risk Quote: “The patient, surgeon and Infec-
tion Control office had no knowledge of
the patient assignments”.
Comment: blinding of treatment providers
done
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “The patient, surgeon and Infec-
tion Control office had no knowledge of
the patient assignments. The code was bro-
ken after initial data evaluation”.
Comment: blinding of outcome assessors
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Nine patients were excluded from
the study after randomisation (one patient
did not undergo surgical treatment, one
underwent biopsy only, five patients failed
to receive a complete course of antibiotics
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and two had antibiotics for another reason”
Comment: the number lost to follow-up is
low and the reasons were valid
Selective outcome data Low risk Comment: the study protocol was not
available but the important outcome mea-
sures stated in the methods section are re-
ported in the results
Other sources of potential bias Low risk Comment: the study appears to be free of
other sources of bias
Yetim 2010
Methods RCT: patients were randomly allocated into 1 of 2 groups
No loss to follow-up
Intention-to-treat analysis: done as all the participants were analysed in the groups to
which they were randomised
Power calculation: not done
Reliable primary outcome: done
Participants All female patients who were diagnosed with breast cancer and underwent modified
radical mastectomy with axillary dissection between June 2006 and June 2009 were
included
Exclusion criteria: patients with inflammatory breast cancer who had neoadjuvant ra-
diotherapy, chronic diseases, e.g. diabetes, immune suppression, were excluded
Treatment group: 22
Control group: 22
Interventions I) Gentacoll applied to the axillary area and under the flap before closure of the surgical
wound. Two pieces of Gentacoll were used in each area. Gentacoll is 10 cm x 10 cm x
0.5 cm collagen from equine tendons with 200 mg gentamycin sulphate
C) No Gentacoll
Outcomes Wound infection
Seroma formation
Drain removal time
Total drainage volumes
Duration of hospital stay
Notes Length of follow-up: 6 months
Country of origin: Turkey
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly allocated
in to one of two groups”
Comment: no further information regard-
ing randomisation is given
Allocation concealment (selection bias) Unclear risk Comment: no information is given regard-
ing the concealment of randomisation
Blinding (performance bias and detection
bias)
Participants
High risk Quote: “Group I underwent modified rad-
ical mastectomy during which Gentacoll
was applied to the axiliary area and under
the flap area of the breast before closure
of the surgical wound. Two pieces of Gen-
tacoll were used for each area, each com-
prising 10 x 10 x 0.5 cm collagen plus
gentamycin sulphate (200 mg). Group II
underwent modified radical mastectomy
without the application of Gentacoll.”
Comment: it is not clear whether the par-
ticipants were blinded in the study, how-
ever, they may be aware of four 10 x 10 x
0.5 cm collagen placed under the skin and
were therefore unable to be blinded
Blinding (performance bias and detection
bias)
Treatment Provider
High risk Quote: “Group I underwent modified rad-
ical mastectomy during which Gentacoll
was applied to the axiliary area and under
the flap area of the breast before closure
of the surgical wound. Two pieces of Gen-
tacoll were used for each area, each com-
prising 10 x 10 x 0.5 cm collagen plus
gentamycin sulphate (200 mg). Group II
underwent modified radical mastectomy
without the application of Gentacoll.”
Comment: as the surgeonswere responsible
for applying the Gentacoll they could not
be blinded in the study
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Quote: “patients were followed up 7 days
after discharge from hospital and at 1, 3
and 6 months after surgery”
Comment: no information is given as to
who performed the follow-up and whether
or not they were blinded. At follow-up
would infection and seroma formation was
assessed as well as drain information and
duration of hospital stay. It could be con-
sidered that the healthcare professional as-
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sessing for wound infection would be able
to see if collagen implants hadbeen inserted
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there was no loss to follow-up
documented in the study. 44 patients were
enrolled and randomised and the results ta-
bles given follow-up data for all 44 partic-
ipants. However, the authors state that pa-
tients would be followed up for 6 months
post surgery, the only information given in
the paper is for the first 7 days
Selective outcome data Low risk Comment: the
study protocol was not available, however,
wound infection, seroma formation, drain
removal time, total drainage volumes and
duration of hospital stay were recorded and
displayed in results tables 2 and 3
Other sources of potential bias Low risk Comment: the study appears to be free
from other sources of bias
C: control
I: intervention
IV: intravenous
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baker 2000 This study was from the perspective of dentists managing risk in patients undergoing dental work who are at risk
of remote infection due to implants, not infection risk as an acute surgical complication
Bertin 1998 Not a RCT or quasi-RCT
Boyd 1981 Not a RCT, retrospective analysis
D’Amico 2001 Review
Erfle 2002 Not a RCT or quasi-RCT
Esposito 2006 Study includes hernia repair and breast cancer surgery. Unable to separate data for breast patients
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(Continued)
Exener 1992 Unable to obtain through the British Library
Franchelli 1994 Although the data were on reconstructive surgery, the paper did not state being secondary to breast cancer
treatment. It also did not state whether the surgery was immediate or delayed reconstruction
Hall 2000 Review
LeRoy 1991 Excluded as retrospective analysis
Lewis 1995 Excluded as unable to obtain separate data for breast patients despite writing to the author
Morimoto 1998 Excluded as this study was comparing antibiotic dose and regime rather than antibiotic versus placebo/none
Pennel 2004 Not a RCT or quasi-RCT
Platt 1992 Not a RCT or quasi-RCT
Platt 1993 This is a meta-analysis of Platt (1990) and Platt (1992). Platt 1992 was not a RCT and Platt 1990 has been used
within this systematic review.
Sanguinetti 2009 Removal of benign lesions included in study. No separate data was obtainable for breast cancer patients
Sasaki 1988 Excluded as not a RCT following translation. No comparison made
Serletti 1994 Addressed reduction mammoplasty. Surgery not cancer-related.
Shamilov 1991 Not a RCT or quasi-RCT
Spicher 2003 Found not to be a RCT following translation. The article analyses the authors experience of implementing
guidelines for using antibiotics with patients undergoing reconstructive surgery
Sultan 1989 No separate data were obtainable for breast patients
Thomas 1999 Addresses long-acting versus short-acting antibiotic comparison rather than antibiotic versus none or placebo
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Baker 2005
Methods
Participants
Interventions
Outcomes
Notes Awaiting clarification of study details from the author
Kumar 2005
Methods
Participants
Interventions
Outcomes
Notes Awaiting clarification of study details from the author
Melling 2005
Methods
Participants
Interventions
Outcomes
Notes Awaiting clarification of study details from the author
Melling 2006
Methods
Participants
Interventions
Outcomes
Notes Awaiting clarification of study details from the author
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D A T A A N D A N A L Y S E S
Comparison 1. Preoperative antibiotics versus none or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Wound infections 8 2236 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.53, 0.94]
1.1 Preoperative antibiotic
versus placebo
6 1566 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.52, 0.96]
1.2 Preoperative antibiotic
versus none
2 670 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.32, 1.56]
2 Wound infection cefonicid 2 747 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.33, 0.95]
3 Infection rates in those who
received neo-adjuvant chemo
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.12]
4 Cost of care Other data No numeric data
5 Adverse effects from antibiotics Other data No numeric data
5.1 Preoperative antibiotics
versus placebo
Other data No numeric data
5.2 Preoperative antibiotics
versus none
Other data No numeric data
6 Time to onset of infection Other data No numeric data
6.1 Preoperative antibiotic
versus placebo
Other data No numeric data
7 Readmission to hospital 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Preoperative antibiotics
versus placebo
2 784 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.04, 3.49]
Comparison 2. Perioperative antibiotics compared with no antibiotic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Wound infection 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 1 Wound infections.
Review: Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
Comparison: 1 Preoperative antibiotics versus none or placebo
Outcome: 1 Wound infections
Study or subgroup Antibiotic Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Preoperative antibiotic versus placebo
Amland 1995 3/42 4/34 0.61 [ 0.15, 2.53 ]
Bold 1998 3/69 10/72 0.31 [ 0.09, 1.09 ]
Gupta 2000 29/164 32/169 0.93 [ 0.59, 1.47 ]
Paajanen 2009 8/144 13/148 0.63 [ 0.27, 1.48 ]
Platt 1990 17/303 26/303 0.65 [ 0.36, 1.18 ]
Wagman 1990 3/59 5/59 0.60 [ 0.15, 2.40 ]
Subtotal (95% CI) 781 785 0.71 [ 0.52, 0.96 ]
Total events: 63 (Antibiotic), 90 (Control)
Heterogeneity: Chi2 = 3.31, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
2 Preoperative antibiotic versus none
Chow 2000 0/28 0/24 0.0 [ 0.0, 0.0 ]
Hall 2006 10/311 14/307 0.71 [ 0.32, 1.56 ]
Subtotal (95% CI) 339 331 0.71 [ 0.32, 1.56 ]
Total events: 10 (Antibiotic), 14 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1120 1116 0.71 [ 0.53, 0.94 ]
Total events: 73 (Antibiotic), 104 (Control)
Heterogeneity: Chi2 = 3.31, df = 6 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours Antibiotic Favours Control
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Analysis 1.2. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 2 Wound infection
cefonicid.
Review: Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
Comparison: 1 Preoperative antibiotics versus none or placebo
Outcome: 2 Wound infection cefonicid
Study or subgroup Cefonicid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bold 1998 3/69 10/72 27.3 % 0.31 [ 0.09, 1.09 ]
Platt 1990 17/303 26/303 72.7 % 0.65 [ 0.36, 1.18 ]
Total (95% CI) 372 375 100.0 % 0.56 [ 0.33, 0.95 ]
Total events: 20 (Cefonicid), 36 (Control)
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours cefonicid Favours control
Analysis 1.3. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 3 Infection rates in
those who received neo-adjuvant chemo.
Review: Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
Comparison: 1 Preoperative antibiotics versus none or placebo
Outcome: 3 Infection rates in those who received neo-adjuvant chemo
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bold 1998 0/23 2/24 100.0 % 0.21 [ 0.01, 4.12 ]
Total (95% CI) 23 24 100.0 % 0.21 [ 0.01, 4.12 ]
Total events: 0 (Antibiotic), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
38Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 4 Cost of care.
Cost of care
Study Antibiotic Placebo Cost calculation
Bold 1998 Total cost in the treatment group:
USD 4382.57
Average per patient: USD 49.80
Total cost in the placebo group: USD
32,838.16
Average per patient: USD 364.87
Treatment costs were calculated from:
cost of prophylaxis administration,
charges for outpatient treatment and
charges for inpatient treatment
Analysis 1.5. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 5 Adverse effects
from antibiotics.
Adverse effects from antibiotics
Study Antibiotic Control
Preoperative antibiotics versus placebo
Amland 1995 Side effects considered by the investigator to be related to
treatmentwere recorded in 4 of the 171 patients receiving
the antibiotic (2.3%)
2 GI; 1 skin rash; 1 other
Side effects considered by the investigator to be related
to treatment were present in 5 of the control group (3.
0%)
2 GI; 2 skin rash; 1 other
Bold 1998 Stated as: “no patient suffered a complication related to
the antibiotic administration”
None recorded
Gupta 2000 41 adverse events noted, details not provided as to
whether these were per patient or per event
33 adverse events noted, details not provided as to
whether these were per patient or per event
Paajanen 2009 None recorded None recorded
Platt 1990 None recorded None recorded
Wagman 1990 Stated as: “no untoward reactions” Stated as: “no untoward reactions”
Preoperative antibiotics versus none
Chow 2000 No adverse events recorded No adverse events recorded
Hall 2006 Stated as ’no side effects observed’ from the flucloxacillin None stated
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Analysis 1.6. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 6 Time to onset of
infection.
Time to onset of infection
Study Antibiotic Control
Preoperative antibiotic versus placebo
Gupta 2000 Mean time to onset of infection 12 days Mean time to onset of infection 11 days
Platt 1990 Mean time to onset of infection 11 days Mean time to onset of infection 10 days
Wagman 1990 Mean time to onset of infection 17.7 days
Analysis 1.7. Comparison 1 Preoperative antibiotics versus none or placebo, Outcome 7 Readmission to
hospital.
Review: Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
Comparison: 1 Preoperative antibiotics versus none or placebo
Outcome: 7 Readmission to hospital
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Preoperative antibiotics versus placebo
Bold 1998 1/88 9/90 43.2 % 0.11 [ 0.01, 0.88 ]
Platt 1990 5/303 5/303 56.8 % 1.00 [ 0.29, 3.42 ]
Subtotal (95% CI) 391 393 100.0 % 0.39 [ 0.04, 3.49 ]
Total events: 6 (Antibiotic), 14 (Control)
Heterogeneity: Tau2 = 1.80; Chi2 = 3.43, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.84 (P = 0.40)
0.001 0.01 0.1 1 10 100 1000
Favours Antibiotic Favours Control
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Analysis 2.1. Comparison 2 Perioperative antibiotics compared with no antibiotic, Outcome 1 Wound
infection.
Review: Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
Comparison: 2 Perioperative antibiotics compared with no antibiotic
Outcome: 1 Wound infection
Study or subgroup Gentamycin No antibiotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yetim 2010 0/22 4/22 0.11 [ 0.01, 1.95 ]
0.002 0.1 1 10 500
Favours gentamycin Favours no antibiotic
A P P E N D I C E S
Appendix 1. Search strategy for the original version of this review
We searched for published and unpublished trials using the following electronic databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2006)
• Cochrane Wounds Group Specialised Register (February 2006)
• Cochrane Breast Cancer Group Specialised Register (March 2005)
• MEDLINE 2002 to 2004 (earlier years were searched via CENTRAL)
• EMBASE 1980 to 2004 (earlier years were searched via CENTRAL)
• CINAHL 1982 to 2004
• NRR Issue 1, 2005
• SIGLE 1976 to 2004
The search strategy used to search T he Cochrane Library Issue 1, 2006 is outlined below. This search strategy was used for searching
all databases, however, it was amended to meet the specific requirements of each search interface.
1. BREAST CANCER explode all trees (MeSH)
2. (breast near cancer*)
3. (breast near neoplasm*)
4. (breast near carcinoma*)
5. (#1 or #2 or #3 or #4)
6. PREOPERATIVE CARE single term (MeSH)
7. PERIOPERATIVE CARE explode all trees (MeSH)
8. POSTOPERATIVE CARE explode all trees (MeSH)
9. POSTOPERATIVE COMPLICATIONS explode tree 1 (MeSH)
10. SURGICAL WOUND INFECTION single term (MeSH)
11. (surger* or surgical or operation*)
12. (operating next room*)
13. (operating next theater*) ** note American spelling
14. ((pre next operative) or preoperative)
15. ((peri next operative) or perioperative)
16. ((post next operative) or postoperative)
17. MAMMAPLASTY explode tree 1 (MeSH)
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18. BREAST IMPLANTATION single term (MeSH)
19. (breast next implants)
20. (breast near implant*)
21. (breast near augmentation*)
22. (silicone near implant*)
23. (saline near implant*)
24. (breast near reconstruction*)
25. mastectomy
26. (#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #
24 or #25)
27. ANTI-BACTERIAL AGENTS explode tree 1 (MeSH)
28. antibiotic*
29. ((anti next bacterial*) or antibacterial*)
30. ((anti next microbial*) or antimicrobial*)
31. (anti next infect*)
32. clindamycin
33. (cefuroxime or cefuroxim)
34. ceftazidime
35. ofloxacin
36. levofloxacin
37. azithromycin
38. sulbactam
39. ampicillin
40. mezlocillin
41. oxacillin
42. vancomycin
43. tobramycin
44. ciprofloxacin
45. (#27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44)
46. (#5 and #26 and #45)
Appendix 2. Ovid MEDLINE search strategy
1 exp Surgical Wound Infection/
2 (surg$ adj5 infection$).mp.
3 (surgical adj5 wound$).mp.
4 ((postoperative or post-operative) adj5 infection$).mp.
5 exp Preoperative Care/
6 ((preoperative or pre-operative) adj care).mp.
7 exp Perioperative Care/
8 ((perioperative or peri-operative) adj care).mp.
9 or/1-8
10 Breast Neoplasms/su [Surgery]
11 (breast cancer$ adj5 surg$).mp.
12 (breast neoplasm$ adj5 surg$).mp.
13 (breast carcinoma$ adj5 surg$).mp.
14 exp Mastectomy/
15 exp Mammaplasty/
16 (mastectomy or mammaplasty).mp.
17 exp Breast/su [Surgery]
18 or/10-17
19 9 and 18
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20 exp Anti-Bacterial Agents/
21 (antibiotic$ or clindamycin or cefuroxime or cefuroxim or ceftazidime or ofloxacin or levofloxacin or azithromycin or sulbactam
or ampicillin or mezlocillin or oxacillin or vancomycin or tobramycin or ciprofloxacin).mp.
22 or/20-21
23 19 and 22
Appendix 3. Ovid EMBASE search strategy
1 exp Surgical Infection/
2 (surg$ adj5 infection$).ti,ab.
3 (surgical adj5 wound$).ti,ab.
4 ((postoperative or post-operative) adj5 infection$).ti,ab.
5 exp Preoperative Care/
6 ((preoperative or pre-operative) adj care).ti,ab.
7 exp Perioperative Period/
8 ((perioperative or peri-operative) adj care).ti,ab.
9 or/1-8
10 exp Breast Tumor/su [Surgery]
11 (breast cancer$ adj5 surg$).ti,ab.
12 (breast neoplasm$ adj5 surg$).ti,ab.
13 (breast carcinoma$ adj5 surg$).ti,ab.
14 exp MASTECTOMY/
15 exp Breast Reconstruction/
16 (mastectomy or mammaplasty).ti,ab.
17 exp Breast Surgery/
18 or/10-17
19 9 and 18
20 exp Antiinfective Agent/
21 (antibiotic$ or clindamycin or cefuroxime or cefuroxim or ceftazidime or ofloxacin or levofloxacin or azithromycin or sulbactam
or ampicillin or mezlocillin or oxacillin or vancomycin or tobramycin or ciprofloxacin).ti,ab.
22 or/20-21
23 19 and 22
Appendix 4. EBSCO CINAHL search strategy
S23 S11 and S19 and S22
S22 S20 or S21
S21 TI ( antibiotic* or clindamycin or cefuroxime or cefuroxim or ceftazidime or ofloxacin or levofloxacin or azithromycin orsulbactam
or ampicillin ormezlocillin or oxacillin or vancomycin or tobramycin or ciprofloxacin ) or AB ( antibiotic* or clindamycin or cefuroxime
or cefuroxim or ceftazidime or ofloxacin or levofloxacin or azithromycin orsulbactam or ampicillin or mezlocillin or oxacillin or
vancomycin or tobramycin or ciprofloxacin )
S20 (MH “Antibiotics+”)
S19 S12 or S13 or S14 or S15 or S16 or S17 or S18
S18 (MH “Breast/SU”)
S17 TI ( mastectomy or mammaplasty ) or AB ( mastectomy or mammaplasty )
S16 (MH “Mastectomy+”)
S15 TI breast carcinoma* N5 surg* or AB breast carcinoma* N5 surg*
S14 TI breast neoplasm* N5 surg* or AB breast neoplasm* N5 surg*
S13 TI breast cancer* N5 surg* or AB breast cancer* N5 surg*
S12 (MH “Breast Neoplasms/SU”)
S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S10 TI ( perioperative care or peri-operative care ) or AB ( perioperative care or peri-operative care )
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S9 (MH “Perioperative Care+”)
S8 TI ( preoperative care or pre-operative care ) or AB ( preoperative care or pre-operative care )
S7 (MH “Preoperative Care+”)
S6 TI ( postoperative* N5 infection* OR post-operative* N5 infection* ) or AB ( postoperative* N5 infection* OR post-operative* N5
infection* )
S5 TI wound* N5 infection* or AB wound* N5 infection*
S4 TI surg* N5 wound* or AB surg* N5 wound*
S3 TI surg* N5 infection* or AB surg* N5 infection*
S2 (MH “Surgical Wound Dehiscence”)
S1 (MH “Surgical Wound Infection”)
Appendix 5. Risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of randomnumbers); assignment envelopes were usedwithout appropriate
safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
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3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Any one of the following.
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
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Unclear
Any one of the following.
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Any of the following.
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon)
High risk of bias
Any one of the following.
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• had extreme baseline imbalance; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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WH A T ’ S N E W
Last assessed as up-to-date: 31 August 2011.
Date Event Description
23 September 2011 New citation required but conclusions have not
changed
New authors added to the review
31 August 2011 New search has been performed Second update, new searches, two studies added
(Paajanen 2009; Yetim 2010), two studies excluded
(Esposito 2006; Sanguinetti 2009).
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 2, 2006
Date Event Description
11 August 2009 Amended Contact details updated.
24 October 2008 New search has been performed One new trial added. Conclusions unchanged.
28 July 2008 Amended Converted to new review format.
18 December 2005 New citation required and conclusions have changed Substantive amendment
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Hertfordshire, UK.
• Department of Health Sciences, University of York, York, UK.
External sources
• NIHR/Department of Health (England), (Cochrane Wounds Group), UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antibiotic Prophylaxis; Breast Neoplasms [∗surgery]; Randomized Controlled Trials as Topic; Surgical Wound Infection [∗prevention
& control]
MeSH check words
Female; Humans
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